-
-
18+
-
Active, Not Recruiting
Active, Not Recruiting
Real-Life Efficacy and Safety of Nivolumab Monotherapy or in Combination With Ipilimumab in Patients With Advanced (Unresectable or Metastatic) Melanoma
Real-Life Efficacy and Safety of Nivolumab monotherapy or in combination with Ipilimumab in Patients with Advanced (Unresectable or Metastatic) Melanoma
Inclusion Criteria: - ≥ 18 years - advanced melanoma (Stage III/Stage IV) - histologically confirmed diagnosis - treatment decision for nivolumab mono- or combination therapy already taken - signed informed consent Exclusion Criteria: - current primary diagnosis of a cancer other than advanced melanoma, that requires systemic or other treatment - previous treatment with nivolumab - current active participation in an interventional clinical trial for treatment of advanced melanoma
Adjuvant Nivolumab therapy
Nivolumab Monotherapy patients
Nivolumab/Ipilimumab Combination therapy patients
Recomendamos encarecidamente que se comunique con BMS para informar los efectos secundarios (eventos adversos)
Los efectos secundarios (eventos adversos) y otros eventos reportables se definen aquí
Informe de efectos secundarios (eventos adversos) o quejas sobre la calidad del producto: información médica